Use of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer.

TitleUse of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer.
Publication TypeJournal Article
Year of Publication2006
AuthorsGozgit JM, Pentecost BT, Marconi SA, Otis CN, Wu C, Arcaro KF
JournalMolecular cancer research : MCR
Volume4
Issue12
Pagination905-13
Date Published2006 Dec
ISSN1541-7786
KeywordsBreast Neoplasms, Cell Adhesion Molecules, Cell Line, Tumor, Cytoskeletal Proteins, Female, Humans, Neoplasm Invasiveness, Polymerase Chain Reaction, Receptors, Estrogen
AbstractAn estrogen receptor-negative variant of the MCF-7 breast cancer cell line, TMX2-28, was used as a model in which to study breast cancer cell invasion. Using a reconstituted basement membrane (Matrigel) assay to evaluate cell invasion, we determined that TMX2-28 cells are more invasive than MCF-7 cells and that the invasiveness of TMX2-28 is similar to that of the aggressive MDA-MB-231 breast cancer cell line. TMX2-28 cells displayed a rounded, epithelial cell-like morphology, suggesting an amoeboid mode of cell invasion, in contrast to the mesenchymal mode of invasion characteristic of spindle-shaped, fibroblast-like MDA-MB-231 cells. Using real-time reverse transcription-PCR, we found that mitogen-inducible gene 2 (MIG2) is expressed at a 17-fold higher level in TMX2-28 cells than in nonaggressive MCF-7 cells and that MIG2 mRNA levels are low in the nontumorigenic human mammary epithelial cell line, 184. We determined that MIG2 plays a role in cell invasion by using small interfering RNA (siRNA) to suppress the expression of MIG2 mRNA levels in TMX2-28 cells. TMX2-28 cell invasion was reduced by 48% when the cells were transfected with siRNAs targeting MIG2, relative to cells transfected with siRNAs against glyceraldehyde-3-phosphate dehydrogenase. Finally, MIG2 expression was evaluated in reductive mammoplasty and breast tumor tissue. Although all 21 normal tissues from reduction mammoplasty showed immunoreactivity for MIG2, ranging from weak (62%) to strong (24%), only half of the 34 formalin-fixed breast tumors showed immunoreactivity for MIG2. Of these 17 positive cases, 10 were considered to overexpress MIG2 (moderate to strong staining). Examination of 30 frozen breast tumors supported the finding that MIG2 is overexpressed in a subset of breast cancers. We suggest that MIG2’s normal regulation and function are disrupted in breast cancer.
DOI10.1158/1541-7786.MCR-06-0147
Alternate JournalMol. Cancer Res.
PubMed ID17189381